-
公开(公告)号:US12129256B2
公开(公告)日:2024-10-29
申请号:US17939375
申请日:2022-09-07
Applicant: PFIZER INC.
Inventor: Matthew Frank Brown , Alpay Dermenci , Andrew Fensome , Brian Stephen Gerstenberger , Matthew Merrill Hayward , Dafydd Rhys Owen , Stephen Wayne Wright , Li Huang Xing , Xiaojing Yang
IPC: A61K31/4985 , C07D487/04
CPC classification number: C07D487/04 , A61K31/4985
Abstract: A compound having the structure:
or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A, A′ and A″ are independently O, C═O, C—R′ or N—R″, where R′ and R″ may independently be H, amino, —NR7COR6, COR6, —CONR7R8, C1-C6 alkyl, or hydroxy(C1-C6 alkyl), and R″ may be present or absent, and is present where the rules of valency permit, and where not more than one of A, A′ and A″ is O or C═O; R0 and R are independently H, Br, Cl, F, or C1-C6 alkyl; R1 is H, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R2 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, hydroxy(C1-C6 alkyl), phenyl(C1-C6 alkyl), formyl, heteroaryl, heterocyclic, —COR6, —OCOR6, —COOR6, —NR7COR6, —CONR7R8, and —(CH2)n—W, where W is cyano, hydroxy, C3-C8 cycloalkyl, —SO2NR7R8, and —SO2—R9, where R9 is C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, or heterocyclic; wherein each of said alkyl, cycloalkyl, heterocyclic, or heteroaryl may be unsubstituted or substituted by halo, cyano, hydroxy, or C1-C6 alkyl; X is C—R3 or N, where R3 may be H or C1-C6 alkyl; R4 and R5 are independently H, amino, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R6, R7 and R8 are each independently H, C1-C6 alkyl, C1-C4 alkoxy(C1-C6 alkyl), or C3-C8 cycloalkyl, said C1-C6 alkyl is optionally substituted by halo, CN or hydroxy; or, R7 and R8 together with the atom bonded thereto form a 5- or 6-membered ring, said ring being optionally substituted by halo, hydroxy, CN, or C1-C6 alkyl; and, n is 0, 1, 2 or 3. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.-
公开(公告)号:US11541034B2
公开(公告)日:2023-01-03
申请号:US17554091
申请日:2021-12-17
Applicant: Pfizer Inc.
Inventor: Dafydd Rhys Owen , Martin Youngjin Pettersson , Matthew Richard Reese , Matthew Forrest Sammons , Jamison Bryce Tuttle , Patrick Robert Verhoest , Liuqing Wei , Qingyi Yang , Xiaojing Yang
IPC: A61K31/401 , A61K31/403 , C07D403/12 , A61K31/427 , A61P31/14
Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
-
公开(公告)号:US20220142976A1
公开(公告)日:2022-05-12
申请号:US17554091
申请日:2021-12-17
Applicant: Pfizer Inc.
Inventor: Dafydd Rhys Owen , Martin Youngjin Pettersson , Matthew Richard Reese , Matthew Forrest Sammons , Jamison Bryce Tuttle , Patrick Robert Verhoest , Liuqing Wei , Qingyi Yang , Xiaojing Yang
IPC: A61K31/403 , A61K31/427 , A61P31/14 , C07D403/12
Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
-
公开(公告)号:US20230120254A1
公开(公告)日:2023-04-20
申请号:US17932151
申请日:2022-09-14
Applicant: Pfizer Inc.
Inventor: Dafydd Rhys Owen , Matthew Richard Reese , Matthew Forrest Sammons , Jamison Bryce Tuttle , Patrick Robert Verhoest , Qingyi Yang
IPC: A61K31/403 , A61P31/14 , A61K31/427 , C07D403/12 , A61K31/401
Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
-
公开(公告)号:US20220062232A1
公开(公告)日:2022-03-03
申请号:US17395139
申请日:2021-08-05
Applicant: Pfizer Inc.
Inventor: Dafydd Rhys Owen , Martin Youngjin Pettersson , Matthew Richard Reese , Matthew Forrest Sammons , Jamison Bryce Tuttle , Patrick Robert Verhoest , Liuqing Wei , Qingyi Yang , Xiaojing Yang
IPC: A61K31/403 , C07D403/12 , A61K31/427 , A61P31/14
Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
-
公开(公告)号:US20200172537A1
公开(公告)日:2020-06-04
申请号:US16638271
申请日:2018-08-09
Applicant: Pfizer Inc.
Inventor: Brian Stephen Gerstenberger , Andrew Fensome , Dafydd Rhys Owen , Matthew Frank Brown , Matthew Merrill Hayward , Felix Vajdos , Li Huang Xing , Stephen Wayne Wright
IPC: C07D471/04 , C07D519/00 , C07D401/14 , C07D405/14 , C07D401/04
Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein variables are defined in the specification. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.
-
公开(公告)号:US20230120707A1
公开(公告)日:2023-04-20
申请号:US17906132
申请日:2021-03-31
Applicant: Pfizer Inc.
Inventor: Robert Steven Kania , Dafydd Rhys Owen , Martin Youngjin Pettersson , Matthew Forrest Sammons , Jamison Bryce Tuttle
IPC: C07D403/14 , A61K9/20 , A61K9/00
Abstract: The invention relates to compounds of formula I wherein R1 and R2 are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compound
-
公开(公告)号:US11351149B2
公开(公告)日:2022-06-07
申请号:US17395139
申请日:2021-08-05
Applicant: Pfizer Inc.
Inventor: Dafydd Rhys Owen , Martin Youngjin Pettersson , Matthew Richard Reese , Matthew Forrest Sammons , Jamison Bryce Tuttle , Patrick Robert Verhoest , Liuqing Wei , Qingyi Yang , Xiaojing Yang
IPC: C07D403/12 , A61K31/403 , A61P31/14 , A61K31/427
Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
-
公开(公告)号:US10316018B2
公开(公告)日:2019-06-11
申请号:US16206166
申请日:2018-11-30
Applicant: PFIZER INC.
Inventor: Katherine Lin Lee , Christophe Philippe Allais , Christoph Martin Dehnhardt , Lori Krim Gavrin , Seungil Han , David Hepworth , Arthur Lee , Frank Eldridge Lovering , John Paul Mathias , Dafydd Rhys Owen , Nikolaos Papaioannou , Eddine Saiah , Joseph Walter Strohbach , John David Trzupek , Stephen Wayne Wright , Christoph Wolfgang Zapf
IPC: A61K31/4375 , A61K31/4709 , A61K31/4725 , A61K31/4745 , A61K31/4015 , A61K45/06 , C07D401/12 , C07D413/04 , C07D207/273 , C07D491/18 , C07D471/04 , C07D413/14 , C07D401/14
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号:US10174000B2
公开(公告)日:2019-01-08
申请号:US15754650
申请日:2016-08-16
Applicant: PFIZER INC.
Inventor: Katherine Lin Lee , Christophe Philippe Allais , Christoph Martin Dehnhardt , Lori Krim Gavrin , Seungil Han , David Hepworth , Arthur Lee , Frank Eldridge Lovering , John Paul Mathias , Dafydd Rhys Owen , Nikolaos Papaioannou , Eddine Saiah , Joseph Walter Strohbach , John David Trzupek , Stephen Wayne Wright , Christoph Wolfgang Zapf
IPC: C07D207/273 , C07D401/12 , C07D401/14 , C07D413/04 , C07D413/14 , C07D471/04 , C07D491/18 , A61K31/4015 , A61K31/4375 , A61K31/4709 , A61K31/4725 , A61K31/4745 , A61K45/06
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
-
-
-
-
-
-
-
-